19 Antiphospholipid Syndrome Clinical Trials in Houston, TX (2026)

Q: How do I join a clinical trial in Houston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you.

Recruiting Antiphospholipid Syndrome Studies in Houston

NCT07222761Recruiting

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard tr...

Houston, TXPHASE3915 participantsRegeneron Pharmaceuticals

View Study Details

NCT06393738Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R...

Houston, TXPHASE1329 participantsArvinas Inc.

View Study Details

NCT07306559Recruiting

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

This study is open to adults with advanced germ cell tumours, endometrial cancer, or ovarian cancer whose previous treatments were not successful. People can join the study if they have no remaining t...

Houston, TXPHASE1187 participantsBoehringer Ingelheim

View Study Details

NCT05652335Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and to...

Houston, TXPHASE1180 participantsJanssen Research & Development, LLC

View Study Details

NCT07424833Recruiting

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered o...

Houston, TXPHASE1180 participantsAscentage Pharma Group Inc.

View Study Details

NCT06549790Recruiting

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Le...

Houston, TXPHASE1124 participantsNerviano Medical Sciences

View Study Details

NCT07681596Recruiting

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumuma...

Houston, TXPHASE1101 participantsAstraZeneca

View Study Details

NCT06590961Recruiting

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies....

Houston, TXPHASE194 participantsUbix Therapeutics, Inc.

View Study Details

NCT02926690Recruiting

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cance...

Houston, TXPHASE170 participantsOncoTherapy Science, Inc.

View Study Details

NCT06846606Recruiting

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinica...

Houston, TXPHASE169 participantsAuron Therapeutics, Inc.

View Study Details

NCT06796504Recruiting

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

The MS pilot study will assess the safety and investigate the remyelinating effects of the SetPoint System (study device) in adult patients with patients diagnosed with relapsing-remitting multiple sc...

Houston, TXNA60 participantsSetPoint Medical Corporation

View Study Details

NCT07413861Recruiting

Vaginal Natural Orifice Transluminal Endoscopic (vNOTE) Hysterectomy With Uterosacral Suspension

As the adoption of Vaginal natural orifice transluminal endoscopic surgery (vNOTES) expands, attention is shifting from feasibility studies to the refinement of surgical steps that optimize long-term ...

Houston, TXNA50 participantsThe University of Texas Health Science Center, Houston

View Study Details

NCT05190471Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to asses...

Houston, TXPHASE148 participantsBio-Path Holdings, Inc.

View Study Details

NCT06066359Recruiting

Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma

To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help ...

Houston, TXPHASE144 participantsM.D. Anderson Cancer Center

View Study Details

NCT06287229Recruiting

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CV...

Houston, TXPHASE140 participantsM.D. Anderson Cancer Center

View Study Details

NCT06613217Recruiting

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion....

Houston, TXPHASE135 participantsPacylex Pharmaceuticals

View Study Details

NCT07211737Recruiting

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

The purpose of this study is to find the largest safe dose of i15.NKG2D.zeta-NK cells in combination with C7R.GD2.CAR-T cells, and additionally to evaluate how long they can be detected in patients' b...

Houston, TXPHASE127 participantsBaylor College of Medicine

View Study Details

NCT06376162Recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or...

Houston, TXPHASE120 participantsPedAL BCU, LLC

View Study Details

NCT06786533Recruiting

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety. Up to 18 evaluable adult and 18 evaluable pediat...

Houston, TXPHASE118 participantsHemogenyx Pharmaceuticals LLC

View Study Details

About Antiphospholipid Syndrome Clinical Trials in Houston

Antiphospholipid syndrome is an autoimmune disorder that increases the risk of blood clots in arteries and veins, and pregnancy complications. It occurs when the immune system makes antibodies that attack phospholipids. Treatment primarily involves anticoagulant medications.

There are currently 19 antiphospholipid syndrome clinical trials recruiting participants in Houston, TX. These studies are seeking a combined 2,591 participants. Research is being sponsored by Regeneron Pharmaceuticals, Arvinas Inc., Boehringer Ingelheim and 15 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Antiphospholipid Syndrome Clinical Trials in Houston — FAQ

Are there antiphospholipid syndrome clinical trials in Houston?

Yes, there are 19 antiphospholipid syndrome clinical trials currently recruiting in Houston, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Houston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you about next steps.

Are clinical trials in Houston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Houston studies also compensate for your time and travel.

What antiphospholipid syndrome treatments are being tested?

The 19 active trials in Houston are testing new therapies including novel drugs, biologics, and treatment approaches for antiphospholipid syndrome.

Data updated October 15, 2026 from ClinicalTrials.gov